/term/shiller-pe-ratio/STU:1T3 Syndax Pharmaceuticals (STU:1T3) Shiller PE Ratio
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Syndax Pharmaceuticals Inc (STU:1T3) » Definitions » Shiller PE Ratio

Syndax Pharmaceuticals (STU:1T3) Shiller PE Ratio : (As of Jun. 20, 2024)


View and export this data going back to 2017. Start your Free Trial

What is Syndax Pharmaceuticals Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Syndax Pharmaceuticals Shiller PE Ratio Historical Data

The historical data trend for Syndax Pharmaceuticals's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Syndax Pharmaceuticals Shiller PE Ratio Chart

Syndax Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Syndax Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Syndax Pharmaceuticals's Shiller PE Ratio

For the Biotechnology subindustry, Syndax Pharmaceuticals's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Syndax Pharmaceuticals's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Syndax Pharmaceuticals's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Syndax Pharmaceuticals's Shiller PE Ratio falls into.



Syndax Pharmaceuticals Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Syndax Pharmaceuticals's E10 for the quarter that ended in Mar. 2024 is calculated as:

For example, Syndax Pharmaceuticals's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.782/131.7762*131.7762
=-0.782

Current CPI (Mar. 2024) = 131.7762.

Syndax Pharmaceuticals Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201406 -0.701 100.560 -0.919
201409 -1.269 100.428 -1.665
201412 -0.634 99.070 -0.843
201503 -1.679 99.621 -2.221
201506 -3.533 100.684 -4.624
201509 -7.599 100.392 -9.975
201512 -0.464 99.792 -0.613
201603 -2.559 100.470 -3.356
201606 -0.418 101.688 -0.542
201609 -0.748 101.861 -0.968
201612 -0.559 101.863 -0.723
201703 -0.664 102.862 -0.851
201706 -0.623 103.349 -0.794
201709 -0.571 104.136 -0.723
201712 -0.676 104.011 -0.856
201803 -0.641 105.290 -0.802
201806 -0.633 106.317 -0.785
201809 -0.583 106.507 -0.721
201812 -0.615 105.998 -0.765
201903 -0.469 107.251 -0.576
201906 -0.416 108.070 -0.507
201909 -0.372 108.329 -0.453
201912 -0.396 108.420 -0.481
202003 -0.507 108.902 -0.613
202006 -0.373 108.767 -0.452
202009 -0.391 109.815 -0.469
202012 -0.362 109.897 -0.434
202103 -0.454 111.754 -0.535
202106 -0.365 114.631 -0.420
202109 -0.340 115.734 -0.387
202112 1.602 117.630 1.795
202203 -0.572 121.301 -0.621
202206 -0.587 125.017 -0.619
202209 -0.586 125.227 -0.617
202212 -0.585 125.222 -0.616
202303 -0.551 127.348 -0.570
202306 -0.591 128.729 -0.605
202309 -0.684 129.860 -0.694
202312 -0.917 129.419 -0.934
202403 -0.782 131.776 -0.782

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Syndax Pharmaceuticals  (STU:1T3) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Syndax Pharmaceuticals Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Syndax Pharmaceuticals's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Syndax Pharmaceuticals (STU:1T3) Business Description

Traded in Other Exchanges
Address
35 Gatehouse Drive, Building D, Floor 3, Waltham, MA, USA, 02451
Syndax Pharmaceuticals Inc is a clinical stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. The company's product candidates are entinostat which has direct effects on both cancer cells and immune regulatory cells, SNDX-6352 and SNDX-6352, an anti-CSF-1R monoclonal antibody, to enhance the body's immune response on tumors that have shown sensitivity to immunotherapy. Business activity of the group is primarily functioned through the region of United States.

Syndax Pharmaceuticals (STU:1T3) Headlines

No Headlines